Sichenzia Ross Ference LLP Represents BriaCell Therapeutics Corp. in Nasdaq listing and $25 Million Public Offering 

Press Release – New York, NY – February 26, 2021 – Sichenzia Ross Ference LLP today announced that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSXV: BCT), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, in a public offering of 4,852,353 common units at a public offering price of $4.25 per unit, consisting of one share of common stock and one warrant to purchase one share of common stock, and 1,030,000 pre-funded units at a public offering price of $4.24 per unit, consisting of one pre-funded common stock purchase warrant and one warrant.  The aggregate gross proceeds were approximately $25.0 million. The common shares and warrants trade on the Nasdaq Capital Market under the symbols “BCTX” and “BCTXW”, respectively.  

ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.  

A registration statement on Form F-1 (File No. 333-234292) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on February 23, 2021.

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Avital Perlman, and Arthur Marcus and law clerk Zachary Weiss.

• Author
• Recent Posts

Sichenzia Ross Ference Carmel LLP

SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

• Sichenzia Ross Ference Carmel LLP Represents BriaCell Therapeutics in $15 Million Public Offering - July 16, 2025
• Sichenzia Ross Ference Carmel LLP Represents 60 Degrees Pharmaceuticals in Public Offering of Up to $10 Million - July 15, 2025
• Sichenzia Ross Ference Carmel LLP Represents Viewbix in $4.5 Million Private Placement - July 15, 2025